Latest United States News

Sonic Healthcare delivered a strong FY2026, with underlying net profit up 17% to A$621 million and dividends rising to A$1.08 per share. The next test is whether US efficiencies, LADR synergies and organic growth can offset Swiss fee cuts, a delayed UK contract ramp-up and heavier investment demands.

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Titomic has set 30 November 2026 as its current target to complete a proposed move of its parent company from Australia to the United States. The ASX listing would remain, but investors would hold CHESS Depositary Interests in the new US entity if shareholders, the Court and other conditions approve the scheme.

Stakk says recurring contracts now support 100% of its approximately A$55.2 million FY2027 pro-forma revenue forecast, while fresh international wins are being built into the FY2028 growth story. The company will establish Singapore as its non-US commercial, service and technology hub from November 2026.

News Corp has reported record fiscal 2026 revenue of $9 billion, with Total Segment EBITDA exceeding $1.6 billion and free cash flow reaching $811 million. Dow Jones and digital real estate services led the performance, while the company returned $643 million through share buybacks.

BCAL Diagnostics has begun introducing ClearNote Health’s Avantect Multi-Cancer blood test in Australia, starting with Sydney and Melbourne. The test reported 56.2% sensitivity and 98.4% specificity in a case-control validation study, but the company says a negative result does not rule out cancer.

Silver Mines has secured firm commitments for a $70 million placement, giving the company more funding to advance its Bowdens Silver Project through development approvals and engineering studies. The raise also supports royalty acquisitions, exploration and land access, although nearly 43% of the new shares still require shareholder approval.

Actinogen Medical has completed the final patient visit in its 247-participant XanaMIA Alzheimer’s disease trial, keeping topline results on track for November 2026. The milestone closes patient participation in the pivotal study, but provides no indication yet of whether Xanamem improved outcomes.

Nufarm expects FY26 underlying EBITDA to rise about 25% at the midpoint of its $370 million to $380 million range, while leverage falls from 2.7 times to approximately 2.0 times. The improvement comes alongside a sweeping cost-reduction program, but restructuring charges of up to $110 million post tax remain in the numbers.

Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.

Magnum Mining has completed a 10,000-metre auger programme at its Piracanjuba North ionic adsorption clay rare earths project in Brazil, shifting its focus to a 32.5km² plateau zone. The company is targeting a maiden JORC 2012 Mineral Resource Estimate in November, but the project remains at an early exploration stage with no declared resource or reserve.

Capstone Copper will sell its Cozamin copper-silver-zinc-lead mine in Mexico to Luca Mining for up to US$385 million, including US$275 million in upfront cash. The proposed divestment is designed to strengthen Capstone’s balance sheet and redirect capital towards its growth pipeline.